| Q43199994 | Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy |
| Q34523030 | Muscle channelopathies: the nondystrophic myotonias and periodic paralyses |
| Q55285566 | Myotonia permanens with Nav1.4-G1306E displays varied phenotypes during course of life. |
| Q26747746 | Myotonic disorders: A review article |
| Q35106208 | Sodium and chloride channelopathies with myositis: coincidence or connection? |
| Q33570009 | The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. |
| Q36774714 | The nondystrophic myotonias |
| Q27347910 | Translational approach to address therapy in myotonia permanens due to a new SCN4A mutation |